Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma
- 20 December 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 137 (2), 303-311
- https://doi.org/10.1007/s11060-017-2718-z
Abstract
Gliosarcoma is a rare histopathologic variant of glioblastoma traditionally associated with a poor prognosis. While gliosarcoma may represent a distinct clinical entity given its unique histologic composition and molecular features, its relative prognostic significance remains uncertain. While treatment of gliosarcoma generally encompasses the same standardized approach used in glioblastoma, supporting evidence is limited given its rarity. Here, we characterized 32 cases of gliosarcoma and retrospectively evaluated survival relative to 451 glioblastoma patients diagnosed during the same era within the same institution. Overall, we identified 22 primary gliosarcomas, representing 4.7% of WHO Grade IV primary glioblastomas, and 10 secondary gliosarcomas. With median age of 62, patients were predominately Caucasian (87.5%) and male (65.6%). Tumors with available molecular profiling were primarily MGMT-unmethylated (87.5%), IDH-1-preserved (100%) and EGFR wild-type (100%). Interestingly, while no significant median survival difference between primary gliosarcoma and glioblastoma was observed across the entire cohort (11.0 vs. 14.8 months, p = 0.269), median survival was worse for gliosarcoma specifically among patients who received modern temozolomide-based (TMZ) chemoradiotherapy (11.0 vs. 17.3 months, p = 0.006). Matched-pair analysis also trended toward worse median survival among gliosarcomas (11.0 vs. 19.6 months, log-rank p = 0.177, Breslow p = 0.010). While adjuvant radiotherapy (HR 0.206, p = 0.035) and TMZ-based chemotherapy (HR 0.531, p = 0.000) appeared protective, gliosarcoma emerged as a significantly poor prognostic factor on multivariate analysis (HR 3.27, p = 0.012). Collectively, our results suggest that gliosarcoma may still portend worse prognosis even with modern trimodality therapy.Keywords
This publication has 32 references indexed in Scilit:
- Primary gliosarcoma – clinical experience from a regional cancer centre in north IndiaBritish Journal Of Neurosurgery, 2011
- Clinical characteristics and outcomes for a modern series of primary gliosarcoma patientsCancer, 2010
- Secondary gliosarcoma: a review of clinical features and pathological diagnosisJournal of Neurosurgery, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Adult gliosarcoma: epidemiology, natural history, and factors associated with outcomeNeuro-Oncology, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue componentsGenes, Chromosomes and Cancer, 2002
- Genetic Profile of GliosarcomasThe American Journal of Pathology, 2000
- Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group resultsJournal of Neurosurgery, 1998
- Clinical and pathological study of 24 cases of gliosarcomaJournal of Neurosurgery, 1976